Moreover, the combination of GAS5 expression and SOX2-OT expression can differentiate non-small-cell lung cancer patients from control individuals with increased sensitivity (83.8) and specificity (81.4) compared with those of SOX2-OT expression alone [44]. This evidence concerns the gene OXT and non-small cell lung carcinoma.